Biofrontera

Biofrontera Days Inventory Outstanding

The Days Inventory Outstanding (DIO) of Biofrontera (B8FK.DE) as of Nov 21, 2026 is 599.69. In the previous year, Days Inventory Outstanding (DIO) was 979.22 — a change of -38.76% (lower).

Days Inventory Outstanding

599.69

YoY

-38.76%

Last updated:

Days Inventory Outstanding (DIO) of Biofrontera is 2025 599.69 . Days Inventory Outstanding (DIO) of Biofrontera was 2024 979.22 . It decreases by -38.76% lower compared to the previous year.

The Biofrontera Days Inventory Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Inventory Outstanding
Date
Days Inventory Outstanding
Jan 1, 2018
260.53 EUR
Jan 1, 2019
304.35 EUR
Jan 1, 2020
482.37 EUR
Jan 1, 2021
449.04 EUR
Jan 1, 2022
367.92 EUR
Jan 1, 2023
269.35 EUR
Jan 1, 2024
979.22 EUR
Jan 1, 2025
599.69 EUR
The Biofrontera Days Inventory Outstanding history
YEARDays Inventory OutstandingYoY
599.69-38.76%
979.22+263.55%
269.35-26.79%
367.92-18.07%
449.04-6.91%
482.37+58.49%
304.35+16.82%
260.53-67.21%
794.49-1.37%
805.51+77.79%
453.08-0.53%
455.49—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Days Inventory Outstanding (DIO) of Biofrontera is 599.69 in 2025.

Days Inventory Outstanding (DIO) of Biofrontera changed from 979.22 to 599.69, representing a -38.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Inventory Outstanding (DIO) Biofrontera since 2006 – with annual values, charts, and detailed analysis.

DIO measures the average number of days inventory is held before being sold. Lower values indicate more efficient inventory management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Inventory Outstanding (DIO)'s Biofrontera with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Inventory Outstanding (DIO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Inventory Outstanding (DIO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Biofrontera

All Key Metrics — Biofrontera